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Abstract
Background: Checkpoint inhibitors are a class of agents that employ host’s adaptive immune defenses in fighting
cancer. With many new indications and several ongoing clinical trials in a variety of malignancies, the usage of
these agents is set to increase significantly. One of the key challenges patients and physicians face while using
these drugs is with the appropriate assessment of response to therapy.
Case presentation: We are reporting two patients with lung cancer who were treated with nivolumab and
experienced rapidly accumulating recurrent pleural effusions requiring multiple thoracenteses (6 and 4 times each
for patient 1 and 2 respectively) with in the first few weeks of initiation of therapy and also developed pericardial
effusion with cardiac tamponade requiring pericardiocentesis. Both patients had prior history of malignant spread
to pleural and pericardial space in their disease course. Therapy was continued in the first patient with spontaneous
resolution of effusions after 8 weeks and the disease showed near complete response to treatment on imaging at
16 weeks. Second patient declined to continue further treatment with nivolumab after 3 cycles due to recurrent
effusions and cardiac tamponade, although there was some evidence of clinical response at discontinuation.
Conclusions: Patients with history of malignant involvement of visceral spaces should be monitored closely for
rapidly accumulating effusions and particularly for cardiac tamponade, after initiation of therapy with nivolumab.
This presentation could represent pseudoprogression, and continuation of therapy with close monitoring is prudent
as long as effusions are manageable and there is no definitive evidence of progression elsewhere.
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Background
Nivolumab is among a class of checkpoint inhibitors,
which share the same mechanism of enhancing host
immunity against tumor cells. Nivolumab is an IgG4
antibody that targets programmed death-1 protein (PD-1)
on the T-cell surface. It acts by blocking T-cell interaction
with programmed death ligand −1 protein (PDL-1)
expressed by various cellular components in the tumor
microenvironment [1], resulting in un-inhibition of T-cells
and increased anti-tumor host immunity. As a group,
checkpoint inhibitors have become a promising new
addition to the cancer therapy arsenal, with some new in-
dications and multiple ongoing clinical trials in several
other malignancies.
Therefore, an increasing number of patients with can-
cer will be treated with this new class of drugs. One of
the challenges physicians encounter with usage of these
drugs is with the appropriate assessment of response to
therapy [2]. It is well known that the immune-related
tumor response can result in a transient increase in the
size of tumors followed by regression or appearance of
new lesions in presence of response to therapy elsewhere;
and the response itself may take longer than that seen
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with traditional cytotoxic agents [3]. Biopsies of lesions
have shown that transient progression followed by re-
sponse (called pseudoprogression), is due to inflammation,
edema and necrosis associated with immune cell infiltra-
tion of the tumor deposits [4]. Using traditional response
evaluation criteria in solid tumors (RECIST) would
misclassify tumor responses in such group of patients
with pseudoprogression, and hence guidelines for immune-
related response criteria have been proposed for evaluation
of patients being treated with immunotherapy [5]. These
guidelines were developed originally in melanoma patients
receiving ipilimumab, and generally the incidence of pseu-
doprogression in solid tumor patients is thought to be low,
and the way different solid tumors react to various other
immunotherapy drugs may be different. In a recent review
of 71 patients with metastatic non-small cell lung cancer
who received anti-PD-1 therapy, only 5.6 % of patients who
had treatment past progression per RECIST criteria had
further tumor shrinkage [6]. Due to lack of clarity in several
situations, there have been calls for increased reporting of
immune related response phenomena in solid tumor pa-
tients. This should empower patients and physicians with
the right knowledge when facing an important dilemma of
differentiating true progression from pseudoprogression,
and help them when facing crossroads of considering alter-
native therapies vs. continuing same treatment [7].
Here, we report two patients who developed recurrent
pleural effusions and pericardial effusion with cardiac
tamponade within few weeks after initiation of therapy
with nivolumab. In retrospect, we postulate the likely
cause could have been due to pseudoprogression.
Case presentation 1
A 46-year old male non-smoker presented in December
of 2007 with right supraclavicular lymphadenopathy.
An excision biopsy of the lymph node found small cell
lung cancer. A combined PET-CT (Positron Emission
Tomography-Computed Tomography) scan showed a
5 cm right hilar mass and right paratracheal lymphaden-
opathy. He had no disease elsewhere. An MRI (Magnetic
Resonance Imaging) of the brain was negative for meta-
static disease.
The patient was referred to our institution for treat-
ment in January 2008. He had a low-grade disease and
favorable response to various therapies, and a prolonged
disease course as delineated in Fig. 1. He was initially
treated with cisplatin and etoposide and concurrent radi-
ation therapy. He achieved complete response after 6 cy-
cles of chemotherapy, and subsequently underwent
prophylactic cranial irradiation. He was monitored clin-
ically and by imaging every 3 months. In May 2009 the
disease relapsed with left supraclavicular lymphadenop-
athy, confirmed by excision biopsy. He underwent radi-
ation therapy with concurrent cisplatin and etoposide
for 2 cycles followed by 4 cycles of oral topotecan. He
had complete response again that lasted for a year. He
had 2 further courses with platinum and etoposide due
to relapsed disease in 2010 and 2011. Due to relapse in
his right hilar and paratracheal lymph nodes, he was treated
on a phase I trial of an Aurora kinase inhibitor in 2012 with
a complete response that lasted about 18 months. Then he
progressed to develop aortocaval lymphadenopathy. He
again received carboplatin/etoposide with initial response
but developed a malignant pleural effusion and worsening
retroperitoneal adenopathy after receiving 5 cycles. Over
the next 18 months, he received several agents (topotecan,
everolimus, temozolamide, docetaxel and sunitinib) with
only stable disease as best response. His disease progressed
to involve several organs including brain, spinal cord, liver,
pancreas, adrenals, bone and pleural, pericardial and
peritoneal spaces. During this time he underwent several
palliative procedures including two resections of intra-
medullary metastases, multiple sessions of stereotactic
brain radiation therapy, and ureteral stents to relieve
obstruction.
He was then started on nivolumab (3 mg/kg every
2 weeks) in August 2015 based on preliminary results
from a phase I/II study [8]. He had a transient increase
in right paratracheal tumor size causing Superior Vena
Cava (SVC) syndrome that required stenting of the SVC.
He also developed rapidly accumulating bilateral pleural
effusions requiring a total of six thoracenteses over the
next 8 weeks. He further experienced pericardial effusion
with tamponade requiring pericardiocentesis on week 9
after initiation of nivolumab (Fig. 1). Cytologies from
Fig. 1 Disease course timeline for patient 1. -Pleural effusion requiring thoracentesis. -Pericardiocentesis for pericardial tamponade. -First noted to
have pericardial effusion on imaging. SCLC – Small Cell Lung Cancer, EP – period during which disease was controlled using several cycles of
Etoposide + Platinum, 2nd and 3rd line – period during which several second and third line agents were used including topotecan, everolimus,
temozolamide, docetaxel and sunitinib
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both pleural and pericardial fluid were positive for ma-
lignancy. Pericardial fluid cytology showed 5 % lympho-
cytes. The treatment was continued every 2 weeks
without any break. He had evidence of partial response
at 8 weeks of therapy and near complete response at
16 weeks of therapy in December 2015 (Fig. 2). He did
not require any further pleural or pericardial drainage
after the first 2 months of therapy, and he continues to
remain on treatment to date.
Case presentation 2
Patient 2 is 54-year-old female non-smoker, who was di-
agnosed with adenocarcinoma of lung with liver metas-
tases in May 2012. Molecular analysis revealed EGFR
(Epidermal Growth Factor Receptor) mutation on exon
21. She was mostly treated at a different institution and
visited us a few times for second opinion. She was ini-
tially started on erlotinib and she went to her home
country where it was switched to gefitinib due to skin
rash. She had marked improvement on follow-up PET
scan. She underwent stereotactic body radiation therapy
(SBRT) to the primary lung lesion in right lower lobe
and to the hepatic metastases. She returned to United
States in March 2013 when therapy was switched back
to erlotinib without any side effects. In June 2013 she
developed pleural effusion on the right side and under-
went thoracenteses. Cytology was positive for malig-
nancy. She decided to bring gefitinib from Taiwan and
started using it due to progression. In November 2013,
she developed pericardial effusion with tamponade and
underwent pericardiocentesis. Therapy was switched to
afatinib. She showed objective response, however in
April 2014 she developed progression with metastases
to uterus. She was treated with bevacizumab plus afati-
nib. She had stable disease for about a year when she
progressed in May 2015.
In July 2015, she was started on nivolumab (3 mg/kg
every 2 weeks). She developed recurrent right pleural effu-
sions requiring four thoracenteses over the next 8 weeks
(Fig. 3). She also developed pericardial effusion with car-
diac tamponade and underwent pericardiocentesis 7 weeks
after initiation of nivolumab. Both pleural and pericardial
fluid cytologies were positive for malignancy. Lympho-
cytes accounted for 30 % of cells in pericardial fluid
analysis. She was also treated with prednisone for the
possibility of immune-related Adverse Effect (irAE). Doses
varied between 20– 60 mg daily due to successive tapering
schedules with recurrent effusions. Although her meta-
static thyroid nodule and metastatic skin nodules showed
clinical response after 3 treatments, the patient declined
further treatment with nivolumab after she was admitted
to intensive care for 4 days due to pericardial tamponade
on week 7 of therapy. Unfortunately further attempts to
restart nivolumab by her providers after a good recovery
were also declined by the patient. Within 3 months of
discontinuation, the patient again had progressive dis-
ease and is currently on therapy with osimertinib (due
to detection of EGFR T790M mutation).
Discussion
Both of these patients had a history of malignant pleural
and pericardial effusions in their disease course prior to
the treatment with nivolumab. Following initiation of
therapy with nivolumab, they developed recurrent pleural
Fig. 2 Top- PET-CT images July 2015 showing 3.2 cm left para-tracheal mass with SUV 6.8 (a) and 4.6 × 3.1 cm right para-tracheal mass with SUV
6.5 (b). Also seen are large right and small left pleural effusions. Bottom- PET-CT images from December 2015 showing complete resolution of left
para-tracheal mass, and decreased size of right para-tracheal mass with equivocal hypermetabolism (SUV 2.6) along with complete resolution of
left pleural effusion and residual small right pleural effusion
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effusions that re-accumulated rapidly within few days after
each tap, needing multiple thoracenteses with in the first
8 weeks. Both patients also developed pericardial effusion
with tamponade requiring pericardiocentesis. There have
been no previous reports to our knowledge in the litera-
ture that described this clinical presentation [9].
With respect to recurrent effusions in patient 1, we
considered the possibilities of irAE vs. pseudoprogression
initially; however, as the patient was otherwise doing well
clinically, we were able to manage his recurrent effusions
with repeated fluid aspirations while following him closely.
In retrospect, it seems likely that the recurrent effusions
may have been secondary to pseudoprogression, as they
occurred within the first few weeks of therapy concurrently
with tumor enlargement elsewhere, and they stopped
spontaneously without recurrence after 8 weeks, con-
currently with evidence of response to therapy at other
places. One would have expected irAE to worsen and
not resolve spontaneously with continued therapy. In
case of our second patient who was treated at an out-
side institution at the same time as patient 1, the clin-
ical course followed a similar pattern as seen in patient
1 with respect to recurrent effusions and pericardial
tamponade. She also had an initial increase in the size
of her metastatic thyroid nodule and skin metastases
followed by partial regression after cycle 3. Though we
discussed cautiously monitoring her without steroids,
the patient decided in consultation with her primary
oncologist to initiate prednisone in addition to repeated
fluid aspiration, and subsequently discontinued therapy
after cycle3. Because of the steroid use and the discon-
tinuation of nivolumab, it is difficult to conclude with
any certainty the mechanism of recurrent effusion in
this case; however, the fact that she did show some im-
provement in disease elsewhere suggest that it could be
due to pseudoprogression or irAE. Prior experience with
similar clinical situations or a clear understanding of the
mechanisms behind this clinical phenomenon would have
provided a stronger argument for careful continuation of
therapy with close monitoring. The variation seen in re-
sponse to a similar clinical situation between different
providers highlights the importance of need for in-
creased reporting of these phenomena, and for studies
to understand the underlying mechanisms, in patients
undergoing immunotherapy.
In both cases, the possibility of immune-related serositis
secondary to nivolumab was considered, however, there
was no massive lymphocyte infiltration in the pericardial
fluid analysis in either case. Lymphocytes accounted for
5 % of cells in patient 1, and 30 % of cells in patient 2. In
retrospect, serial flow cytometry of pleural fluid may
have been instructive to better characterize the ongoing
changes within the pleural fluid over time. In both
phase 3 trials of nivolumab vs. docetaxel, pleural or
pericardial effusion as adverse events were not common
[10, 11]. In the squamous non-small cell lung cancer
trial, pleural or pericardial effusions were not reported
as adverse events [11]. Of all-cause adverse events in
the non-squamous non-small cell lung cancer trial,
pleural effusion was reported in 6 % of patients in the
nivolumab arm and 3 % of patients in the docetaxel
arm. Of the treatment-related serious adverse events,
pleural effusion was not reported and pericardial effu-
sion was reported in 1 out of 287 patients (<1 %) in the
nivolumab arm [10]. No attribution of cause is described
in the manuscript for the 6 % of patients who developed
pleural effusions in the nivolumab arm; however, we
would presume that most of these would be attributable
to progressive disease. It is furthermore unknown, how
many patients had pre-existing pleural or pericardial effu-
sions prior to the initiation of nivolumab. Therefore, the
above cases highlight the need to more carefully evaluate
the clinical scenario in patients with worsening effusions,
especially early after initiation of nivolumab therapy.
Conclusion
In conclusion, patients with history of malignant pleural
or pericardial effusions should be monitored closely for
recurrent effusions after initiation of nivolumab therapy.
Such presentation could represent pseudoprogression and
possibly a harbinger of response to therapy. We would
posit that careful continuation of nivolumab without initi-
ation of steroids may be the best approach as long as the
effusions can be managed with drainage, unless there is
clear evidence of progression elsewhere. Careful analysis
of fluid with flow cytometry should be considered in such
Fig. 3 Disease course timeline for patient 2. -Pleural effusion requiring thoracentesis. -Pericardial tamponade requiring pericardiocentesis.
N- Nivolumab
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cases as a large increase in lymphocytes may be an indica-
tion for initiation of steroids. Increased reporting of these
immune related phenomena and studies to understand
mechanisms behind such presentation, are necessary to
guide patients and physicians with appropriate course of
action.
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